Published on 21/12/2025
Ethical and Regulatory Perspectives on Compassionate Use in Rare Disease Treatment
Understanding Compassionate Use and Expanded Access Programs
For patients with rare and life-threatening diseases, conventional treatment options are often limited or nonexistent. When clinical trial participation is not feasible due to geographic, medical, or eligibility limitations, compassionate use—or expanded access—offers a critical alternative pathway for accessing investigational therapies outside of clinical trials. These programs allow patients to receive potentially life-saving treatments before formal regulatory approval, under strict conditions and ethical oversight.
Expanded Access Programs (EAPs) are regulated by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), offering a structured mechanism for pre-approval treatment in exceptional circumstances. In rare disease communities, where the urgency of need is amplified by the lack of alternatives, EAPs are often the only hope for patients with deteriorating conditions.
Regulatory Frameworks Across Different Jurisdictions
The regulatory approach to compassionate use varies by region. Understanding these frameworks is crucial for sponsors and clinicians working in rare disease spaces.
- FDA (USA): Allows expanded access under 21 CFR 312 Subpart I. Individual, intermediate-size, and widespread EAPs are permitted. IRB approval and informed consent are required.
- EMA
For example, a biotech company providing a gene therapy for a rare metabolic disorder implemented a multi-country EAP following positive Phase II results, using local regulations to support early access in Canada, Brazil, and Italy.
Ethical Principles Underpinning Compassionate Use
Despite its noble intent, expanded access raises important ethical considerations, particularly regarding fairness, safety, and resource allocation. Core principles include:
- Equity: Access should not be limited to those with greater resources or advocacy.
- Transparency: Criteria for eligibility and prioritization must be clearly defined.
- Non-maleficence: Risks must be weighed against uncertain benefits.
- Informed consent: Patients must fully understand the experimental nature of the treatment.
- Scientific integrity: Access should not compromise ongoing clinical trials.
For instance, in one EAP for a rare pediatric neurodegenerative condition, the sponsor worked with bioethicists and advocacy groups to design an allocation process that included medical urgency, age limits, and geographic representation as key criteria.
Process for Implementing an Expanded Access Program
Setting up an EAP requires alignment between sponsors, investigators, regulators, and ethics committees. Typical steps include:
- Determine eligibility: Only patients with serious or life-threatening conditions and no alternative treatment options qualify.
- Submit documentation: An IND or protocol amendment must be submitted to FDA or relevant local authority.
- Obtain IRB approval: Even for single-patient access, institutional oversight is necessary.
- Informed consent: Must outline risks, benefits, and the unapproved status of the drug.
- Drug supply coordination: Sponsors must ensure proper labeling, storage, and monitoring of the investigational product.
- Adverse event reporting: Safety data must be collected and reported.
Expanded access is not a “back door” to treatment—it’s a carefully regulated bridge between clinical trials and formal market approval.
Challenges in Compassionate Use Implementation
Despite growing demand, EAPs are logistically and ethically complex. Common challenges include:
- Manufacturing capacity: Sponsors may have limited supplies of the investigational drug.
- Cost recovery: Many jurisdictions prohibit charging patients, posing financial strain on developers.
- Regulatory complexity: Each country has different timelines, documentation, and legal requirements.
- Patient selection: Ethical dilemmas arise when more patients seek access than the program can support.
In a real-world case, a biotech firm offering a rare enzyme replacement therapy faced overwhelming demand. A third-party ethics board was established to manage patient prioritization and ensure fair distribution based on clinical need.
The Role of Advocacy and Patient Engagement
Patient advocacy organizations play a crucial role in facilitating expanded access by:
- Educating families about compassionate use rights and options
- Connecting patients to enrolling EAPs or relevant sponsors
- Lobbying regulators for expedited access in ultra-rare indications
- Helping sponsors understand patient priorities and burdens
For example, advocacy groups like NORD and EURORDIS regularly partner with sponsors to build ethical frameworks for expanded access in ultra-rare diseases, ensuring programs are patient-centered and community-informed.
Right-to-Try Laws: Parallel or Problematic?
Some countries, like the U.S., have implemented “Right-to-Try” legislation allowing patients to directly request investigational drugs without FDA oversight. While this may sound empowering, ethical concerns remain:
- Bypasses standard safety reviews and IRB protections
- Lacks structured adverse event reporting
- Places pressure on sponsors to approve access requests without clear criteria
Many ethicists advocate for structured expanded access over Right-to-Try due to its stronger safeguards and data integrity. Still, both frameworks reflect the growing demand for earlier patient access to promising treatments.
Conclusion: Balancing Compassion and Caution
Compassionate use and expanded access are powerful tools for addressing the unmet needs of rare disease patients. When thoughtfully designed and ethically implemented, these programs offer hope to those who might otherwise face devastating outcomes. Yet they also demand careful balancing of urgency, fairness, and scientific rigor.
Sponsors and clinicians must collaborate with regulators, advocacy groups, and patient families to ensure that these programs remain ethically grounded, transparently administered, and focused on maximizing benefit while minimizing harm. As rare disease therapies continue to evolve, compassionate access will remain a critical complement to traditional clinical trial pathways.